| Followers | 66 |
| Posts | 477 |
| Boards Moderated | 0 |
| Alias Born | 02/26/2019 |
Friday, August 09, 2019 7:49:58 PM
Odd on so many levels.....being gentlemanly, classy or professional it all goes out the window here. Fight, fight, fight is what you want to encourage JT to do. But that’s also the knee jerk reaction.
Seldom does the knee jerk reaction ever gain success. In fact, one could argue the fda wants that reaction as its easier to paint your opponent in poor light.
Instead this is where the under promise over deliver accountant ceo needs to buckle up and get more calculated here. Know those aligning against you and leverage that. Lean on the facts and take this on like an audit.
I wrote previously I don’t fear an adcom and instead welcome it as a stage, coronation type event and I’ve seen much debate here on both sides.
One hand, the FUD, 2013 fears re-emerging, sabotage, ambush, etc.
The other hand, primary label in bag and Adcom focus on secondary, broad label wording
The reality is JT should prepare for the worse, ambush, etc but also use the resources behind you. Goldman Sachs, JPMorgan, Baker, leverage everything and go on offensive but in a stealthy way. Public image, remain classy, conservative, don’t get rattled. Behind the scenes fight w everything. And if that’s using a certain dc law firm to grease wheels then do it. This is where Gwen Fisher comes into play.
I’ve been here before 2013 so scars of old adcom run deep but I’m able to separate past from present and this time i firmly believe JT knows exactly what to do here.
Seldom does the knee jerk reaction ever gain success. In fact, one could argue the fda wants that reaction as its easier to paint your opponent in poor light.
Instead this is where the under promise over deliver accountant ceo needs to buckle up and get more calculated here. Know those aligning against you and leverage that. Lean on the facts and take this on like an audit.
I wrote previously I don’t fear an adcom and instead welcome it as a stage, coronation type event and I’ve seen much debate here on both sides.
One hand, the FUD, 2013 fears re-emerging, sabotage, ambush, etc.
The other hand, primary label in bag and Adcom focus on secondary, broad label wording
The reality is JT should prepare for the worse, ambush, etc but also use the resources behind you. Goldman Sachs, JPMorgan, Baker, leverage everything and go on offensive but in a stealthy way. Public image, remain classy, conservative, don’t get rattled. Behind the scenes fight w everything. And if that’s using a certain dc law firm to grease wheels then do it. This is where Gwen Fisher comes into play.
I’ve been here before 2013 so scars of old adcom run deep but I’m able to separate past from present and this time i firmly believe JT knows exactly what to do here.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
